Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00282581 · ClinicalTrials.gov registry record · Phase 1
Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive
A Phase 1 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00282581 is a Phase 1 study that was terminated before completion, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 2 participants.
The verdict
NCT00282581, a Phase 1 study, was terminated before completion, sponsored by Sanofi Pasteur, a Sanofi Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and immunogenicity of two MVA smallpox vaccine injections in healthy adults that are 18-35 years of age with HIV infection
Interventions
- BIOLOGICAL MVA Smallpox Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00282581
The ClinicalTrials.gov registry entry for NCT00282581 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MVA Smallpox Vaccine is the first listed.
NCT00282581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00282581 about?
NCT00282581 is a clinical study titled "Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive". The purpose of this study is to assess the safety and immunogenicity of two MVA smallpox vaccine injections in healthy adults that are 18-35 years of age with HIV infection
What is the current status of trial NCT00282581?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2006-10. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00282581?
The interventions under investigation include: MVA Smallpox Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00282581?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.